Cane..I'm no scientist, but here's my 2 cents: The mOS declined from interim to final results. The Kazia numbers are still sustantially better than TMZ, the current standard of care. This may have spooked some investors. Next, the data from the other trials was pushed into 2022. Investors have been waiting on these trials for a while. They may have thrown in the towel and moved on. My question to this board is, is there currently any trials ongoing that have better data than Kazia's? Rinnekin will know this.
KZA Price at posting:
$1.17 Sentiment: Buy Disclosure: Held
